Technion and Servier, a partnership of excellence at the service of translational research
In recent years, a new science, translational research, has emerged and promises to become a keystone of tomorrow’s healthcare. Translational research is based on close collaboration between physicians and researchers to bring the therapeutic discoveries from laboratories to patients more quickly and feed fondamental research with knowledge from patients observation. The idea is to link fondamental research, whose goal is to discover the mechanisms of a disease, and clinical research, whose priority is to provide appropriate treatment to patients. For every health player, including Servier, translational medicine represents an opportunity to make treatments more specific and effective for patients.
The Technion and Servier, a partnership of excellence
In pursuit of that goal, Servier has been collaborating for the past 6 years with the Technion working on several innovative research projects, particularly in the fields of immunology applied to oncology as well as in the field of cardiology. Each of these projects demonstrates the scientific excellence and quality of research at the Technion. The number of Nobel Prizes awarded to the institution since the beginning of the twenty-first century — a tie with the Massachusetts Institute of Technology, MIT — is a testament to its excellence. Founded in 1912, Technion is the oldest public research institute and university of Israel, specializing in science and new technologies. With 19 academic departments, a teaching hospital and 52 research centers, it offers to students of second and third cycles, postdoctoral courses and the opportunity to pursue their research in the fields of science, engineering, medicine, industrial management, architecture, urban planning and education.
Mimicking the heart cells in laboratory
Among the projects that Servier is collaborating on, there is the highly acclaimed work of Professor Ofer Binah who has transformed hair cells into cardiac muscle cells, managing to bring them back to the stage of stem cell. Through his work, researchers can “mimic” the diseased heart cells in the laboratory to test new drug candidates.
Advances in Immunology
In other areas such as immunology, Servier supports the work of young researchers in the team of Prof. Yoram Reiter. The team studies the interaction of white blood cells involved in the recognition of cancer cells. Servier also supports the work of Professor Shai Shen Orr, who helped develop a technology called CyTOF. This technology is capable of finely analyzing blood or tissue samples; It can then associate them with cutting-edge technology in order to determine very early on the effectiveness of a treatment at the cellular level, assess possible resistances, or to identify the mechanisms of action of these treatments on an individual scale. This opens the way for personalized medicine, or precision in immuno-oncology. Working with the Technion, either through joint research projects or financial support for advanced technology development within the institute, Servier is committed to its mission of discovering novel and innovative therapeutics approaches to deliver targeted and effective medicines in the near future to improve patient healthcare.
Photo credits : Technion